BioSpace News Archive

Ryvu Therapeutics, a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, today announced that two abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019) in National Harbor, MD from November 6 – 10, 2019.

A new survey from Health Union finds that people with relapsing forms of multiple sclerosis (MS) who currently use a disease-modifying therapy (DMT) report positive relationships with their healthcare professionals (HCP) and interest in prescription therapies, while those who have never used a DMT prefer alternative therapies and have experienced a less straight-forward MS journey than their counterparts

Myeloma Canada is delighted to announce that five leaders within the Canadian community have joined its Board of Directors.

Phase 1 clinical trial results and more favorable effect on the host microbiome vs vancomycin support advancement to Phase 2 in patients with C. difficile Infection (CDI) [03-October-2019] WHITE PLAINS, N.Y. , Oct. 3, 2019 /PRNewswire/ -- Acurx Pharmaceuticals, LLC (“Acurx” or the “Company”), a privately held, clinical stage, biopharmaceutical company developing new a

BD announced that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2019 earnings conference call on Tuesday, November 5, 2019, at 8:00 a.m..

Niraparib, an orally-administered PARP inhibitor, is currently being investigated for the treatment of patients with metastatic castration-resistant prostate cancer and BRCA1/2 DNA repair gene defects

ACADIA Pharmaceuticals Inc. announced that the presentation of the results from the Phase 3 HARMONY study of pimavanserin in dementia-related psychosis has been accepted for a late-breaking oral communication at the upcoming 12th Clinical Trials on Alzheimer’s Disease Meeting, December 4-7, 2019 in San Diego, California.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on October 1, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 79,375 shares of Puma common stock to eleven new non-executive employees.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Progenics Pharmaceuticals, Inc. (NasdaqGS: PGNX) to Lantheus Holdings, Inc.

The president of the American Association of Nurse Practitioners (AANP), Sophia L. Thomas, issued the following statement regarding President Trump’s executive order, entitled Protecting and Improving Medicare for our Nation’s Seniors.